Current Report Filing (8-k)
26 Februar 2019 - 11:17PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 25, 2019
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
Nevada
|
|
000-53605
|
|
26-1265381
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
400 Water Street, Suite 200, Rochester,
MI
|
|
48307
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code:
248.651.6568
___________________________________________________
(Former name or former address, if changed since
last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECTION 1 – Registrant’s Business and Operations
|
Item 1.01
|
Entry into a Material Definitive Agreement
|
Officer Compensation
On February 25, 2019, we executed an amendment
to the employment agreement with William Febbo. The amendment increased the percentage of his target annual bonus from 50% of his
base salary to 60% based on revenue goals and adjusted EBITDA amounts under the terms of our executive bonus plan, as well as adjusted
his remaining outstanding unvested options to vest immediately.
Except as described above, the terms of the
employment agreement with our Mr. Febbo remains in full force and effect.
In addition to the amendment changes described
above, we also awarded $100,000 to Mr. Febbo as a one-time bonus for performance in 2018, in addition to the formula bonus set
forth in his employment agreement. Final bonus amounts payable for 2018 for the executive officers, including the special bonus
to Mr. Febbo, are as follows:
Mr. Febbo
|
|
$
|
294,939
|
|
Mr. Hamilton
|
|
$
|
219,028
|
|
Ms. Paramore
|
|
$
|
131,781
|
|
Mr. Baker
|
|
$
|
124,696
|
|
Finally, we awarded shares of our restricted
common stock our executive officers that will vest only upon achieving certain stretch revenue goals in 2019, as follows:
Officer
|
|
|
Number
of Shares
|
|
Mr. Febbo
|
|
|
30,000 shares
|
|
Ms. Miriam Paramore
|
|
|
10,000 shares
|
|
Mr. Doug Baker
|
|
|
10,000 shares
|
|
In lieu of a restricted stock award, Mr. Hamilton
will be eligible for a bonus of up to $100,000 upon achieving stretch certain revenue goals in 2019.
The foregoing description of the amendment
to employment agreement with Mr. Febbo does not purport to be complete and is qualified in its entirety by reference to the complete
text of the amendment to employment agreement filed as Exhibit 10.1 hereto and incorporated herein by reference.
SECTION 5 – CORPORATE GOVERNANCE AND
MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
The information set forth in Items 1.01 is
incorporated into this Item 5.02 by reference.
SECTION 9 – Financial Statements and Exhibits
|
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OptimizeRx Corporation
|
|
|
|
|
|
|
|
|
/s/ Douglas P. Baker
|
|
|
Douglas P. Baker
|
|
|
Chief Financial Officer
|
|
|
Date: February 26, 2019
|
|
|
|
|
|
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024